HOOKIPA Q2 2022 revenue $2.7M, net loss $16.4M; FDA accepts IND for HB-300, HB-200 Phase 2 underway

HOOKIPA Pharma Inc.

2022-Q2 EPS reported -$0.58 revenue$4,191,000

Revenue $2.7M, down from $5.4M YoY due to lower cost reimbursements from Gilead collaboration.
Net loss $16.4M versus $17.2M in Q2 2021; R&D expenses decreased to $16.1M from $19.6M.
Cash, equivalents and restricted cash $118.9M at June 30, 2022, up from $66.9M at Dec 31, 2021.
FDA accepted IND for HB-300 (metastatic castration-resistant prostate cancer) and Drug Master File for platform.
HB-200 Phase 1 met all endpoints; Phase 2 started; initial data with pembrolizumab expected H2 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.